JP2018521126A5 - - Google Patents

Download PDF

Info

Publication number
JP2018521126A5
JP2018521126A5 JP2018520045A JP2018520045A JP2018521126A5 JP 2018521126 A5 JP2018521126 A5 JP 2018521126A5 JP 2018520045 A JP2018520045 A JP 2018520045A JP 2018520045 A JP2018520045 A JP 2018520045A JP 2018521126 A5 JP2018521126 A5 JP 2018521126A5
Authority
JP
Japan
Prior art keywords
administration
certain embodiments
gw559090a
ocular
ocular administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018520045A
Other languages
English (en)
Japanese (ja)
Other versions
JP6752276B2 (ja
JP2018521126A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/054073 external-priority patent/WO2017006272A1/en
Publication of JP2018521126A publication Critical patent/JP2018521126A/ja
Publication of JP2018521126A5 publication Critical patent/JP2018521126A5/ja
Application granted granted Critical
Publication of JP6752276B2 publication Critical patent/JP6752276B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018520045A 2015-07-08 2016-07-07 眼炎症状態を処置する際に使用するための、インテグリンα4アンタゴニストを含む薬学的組成物 Expired - Fee Related JP6752276B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189813P 2015-07-08 2015-07-08
US62/189,813 2015-07-08
PCT/IB2016/054073 WO2017006272A1 (en) 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020068158A Division JP2020121985A (ja) 2015-07-08 2020-04-06 眼炎症状態を処置する際に使用するための、インテグリンα4アンタゴニストを含む薬学的組成物

Publications (3)

Publication Number Publication Date
JP2018521126A JP2018521126A (ja) 2018-08-02
JP2018521126A5 true JP2018521126A5 (cg-RX-API-DMAC7.html) 2019-08-15
JP6752276B2 JP6752276B2 (ja) 2020-09-09

Family

ID=56373100

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018520045A Expired - Fee Related JP6752276B2 (ja) 2015-07-08 2016-07-07 眼炎症状態を処置する際に使用するための、インテグリンα4アンタゴニストを含む薬学的組成物
JP2020068158A Pending JP2020121985A (ja) 2015-07-08 2020-04-06 眼炎症状態を処置する際に使用するための、インテグリンα4アンタゴニストを含む薬学的組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020068158A Pending JP2020121985A (ja) 2015-07-08 2020-04-06 眼炎症状態を処置する際に使用するための、インテグリンα4アンタゴニストを含む薬学的組成物

Country Status (21)

Country Link
US (3) US10413535B2 (cg-RX-API-DMAC7.html)
EP (1) EP3319639B1 (cg-RX-API-DMAC7.html)
JP (2) JP6752276B2 (cg-RX-API-DMAC7.html)
KR (2) KR102440162B1 (cg-RX-API-DMAC7.html)
CN (1) CN107921136A (cg-RX-API-DMAC7.html)
AU (1) AU2016290197B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018000112A2 (cg-RX-API-DMAC7.html)
CA (1) CA2989522C (cg-RX-API-DMAC7.html)
CL (1) CL2018000057A1 (cg-RX-API-DMAC7.html)
ES (1) ES2835274T3 (cg-RX-API-DMAC7.html)
HK (1) HK1247120A1 (cg-RX-API-DMAC7.html)
IL (2) IL256770B (cg-RX-API-DMAC7.html)
MA (2) MA42016A1 (cg-RX-API-DMAC7.html)
MX (1) MX385229B (cg-RX-API-DMAC7.html)
MY (1) MY187552A (cg-RX-API-DMAC7.html)
PL (1) PL3319639T3 (cg-RX-API-DMAC7.html)
RU (1) RU2018103940A (cg-RX-API-DMAC7.html)
TN (1) TN2017000538A1 (cg-RX-API-DMAC7.html)
UA (1) UA123728C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017006272A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201708601B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165218A1 (en) 2017-03-09 2018-09-13 Allysta Pharmaceuticals, Inc Peptides for dry eye disease
CN110996904A (zh) * 2017-05-19 2020-04-10 奥古根有限公司 眼用组合物及使用方法
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
KR20220054598A (ko) * 2019-07-26 2022-05-03 알레그로 파마슈티칼스, 엘엘씨 비삼출성 황반변성 및 기타 안질환 치료용 펩티드
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP4232458A4 (en) * 2020-10-21 2024-10-02 Azura Ophthalmics Ltd COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISEASES
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828074D0 (en) * 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
SI1881823T1 (sl) * 2005-05-17 2015-04-30 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje bolezni oäśesa
US8067433B2 (en) * 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Similar Documents

Publication Publication Date Title
US8791158B2 (en) Methods of treating meibomian gland dysfunction
US12350277B2 (en) Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
JP6209777B2 (ja) 眼の疾病及び疾患のための組成物及び治療
AU2011284589B2 (en) Compounds for the treatment/prevention of ocular inflammatory diseases
US20080312194A1 (en) Methods and compositions for normalizing meibomian gland secretions
CN107982211A (zh) 眼科治疗
US10292953B2 (en) Pharmaceutical composition of ibuprofen and tramadol for ophthalmic use
CN115192517A (zh) 多泡沫体及其眼睑施用
WO2018033854A1 (en) Ophthalmic composition and a method for treating ocular hypertension and glaucoma
US20260130896A1 (en) Compositions and methods for delivery of ophthalmological actives
US20110130451A1 (en) Method of treating dry eye disorders and uveitis
JPWO2006049250A1 (ja) 眼内移行性促進水性点眼剤
CN116887823A (zh) 用于外用施用加巴喷丁类药物的方法和制剂
CN100522147C (zh) 5,6,7-三羟基庚酸及其类似物在制备治疗干眼病和眼色素层炎药物中的应用
RS64399B1 (sr) Kompozicije za lečenje oftalmoloških stanja
US20070112032A1 (en) Prevention and/or reduction of photoreceptor degeneration with retinoids
TW201705956A (zh) 唑系抗真菌藥之對眼瞼皮膚的投與
CN108348516B (zh) 外用剂
JP7114668B2 (ja) エピナスチン又はその塩を含有する花粉破裂抑制剤
CN117460501A (zh) 用于退行性视网膜疾病的trpa1通道拮抗剂化合物
EA050716B1 (ru) Соединение, принадлежащее к пиразолоновому классу, для применения при дегенеративных заболеваниях сетчатки
HK40031764B (en) Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
HK40031764A (en) Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface